Trials / Completed
CompletedNCT05945927
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
An Observational Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Second- or Later-Line Therapy in Chinese Patients With HER2 Positive Advanced Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 178 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a post-marketing, observational, multicenter, prospective study. It will investigate the the safety and effectiveness of T-DM1 in the Chinese population in real-world clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab emtansine | Trastuzumab emtansine will be administered as per local clinical practice and local labeling. |
Timeline
- Start date
- 2023-09-13
- Primary completion
- 2025-08-30
- Completion
- 2025-08-30
- First posted
- 2023-07-14
- Last updated
- 2025-10-10
Locations
30 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05945927. Inclusion in this directory is not an endorsement.